Corbus Pharmaceuticals Holding (CRBP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Corbus Pharmaceuticals Holding (CRBP) has a cash flow conversion efficiency ratio of -0.169x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.55 Million) by net assets ($92.15 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Corbus Pharmaceuticals Holding defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Corbus Pharmaceuticals Holding - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Corbus Pharmaceuticals Holding's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Corbus Pharmaceuticals Holding Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Corbus Pharmaceuticals Holding ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AB VILKUSKIU PIEN.EO 029
F:UDW
|
0.050x |
|
Mirae Corporation
KO:025560
|
-0.097x |
|
CVC Brasil Operadora e Agencia
SA:CVCB3
|
0.373x |
|
EcoSynthetix Inc
TO:ECO
|
0.014x |
|
Century Land Joint Stock Company
VN:CRE
|
-0.006x |
|
Dong Phu Rubber JSC
VN:DPR
|
-0.011x |
|
Soc Centrale Bois Scieries Manche SA
PA:CBSM
|
0.037x |
|
Softstar Entertainment
TWO:6111
|
-0.024x |
Annual Cash Flow Conversion Efficiency for Corbus Pharmaceuticals Holding (2012–2024)
The table below shows the annual cash flow conversion efficiency of Corbus Pharmaceuticals Holding from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see Corbus Pharmaceuticals Holding market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $142.43 Million | $-41.79 Million | -0.293x | -105.61% |
| 2023-12-31 | $-6.91 Million | $-36.10 Million | 5.228x | +559.39% |
| 2022-12-31 | $32.99 Million | $-37.54 Million | -1.138x | -63.23% |
| 2021-12-31 | $69.11 Million | $-48.18 Million | -0.697x | +68.33% |
| 2020-12-31 | $45.27 Million | $-99.69 Million | -2.202x | +70.35% |
| 2019-12-31 | $6.16 Million | $-45.72 Million | -7.425x | -579.71% |
| 2018-12-31 | $27.52 Million | $-30.07 Million | -1.092x | -127.09% |
| 2017-12-31 | $57.78 Million | $-27.80 Million | -0.481x | +68.38% |
| 2016-12-31 | $8.92 Million | $-13.57 Million | -1.522x | -194.17% |
| 2015-12-31 | $8.99 Million | $-4.65 Million | -0.517x | -28.43% |
| 2014-12-31 | $5.86 Million | $-2.36 Million | -0.403x | -295.84% |
| 2013-12-31 | $-1.78 Million | $-366.71K | 0.206x | -94.70% |
| 2012-12-31 | $-198.38 | $-769.73 | 3.880x | -- |
About Corbus Pharmaceuticals Holding
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation o… Read more